JSB462 Clinical Trials (2026): 4 Studies for Metastatic Hormone-sensitive Prostate Cancer & Metastatic Prostate Cancer (mCRPC)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 JSB462 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including Metastatic Hormone-sensitive Prostate Cancer & Metastatic Prostate Cancer (mCRPC)) and 491 total planned enrollment. 3 JSB462 clinical trials are actively recruiting at 27 U.S. sites across 18 states. Most recent activity: NCT06991556 (Oct 2035).
Where to Participate: All JSB462 Trial Sites in the U.S. (27 sites across 18 states)
Every actively recruiting JSB462trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | University of California San Diego - Moores Cancer Center | La Jolla92093-0658 | NCT06991556 | Map |
| CA | Saint Johns Cancer Institute | Santa Monica90404 | NCT06991556 | Map |
| CO | Rocky Mountain Cancer Centers | Denver80218 | NCT06991556 | Map |
| CO | Sarah Cannon Research Institute | Denver80218 | NCT07206056 | Map |
| CT | Yale Cancer Center | New Haven06520 | NCT06991556 | Map |
| FL | Advanced Urology Ins Daytona Beach | Daytona Beach32114 | NCT06991556 | Map |
| FL | Sarah Cannon Research Institute | Jacksonville32256 | NCT07206056 | Map |
| GA | Emory University | Atlanta30329 | NCT07206056 | Map |
| GA | Emory University School of Medicine-Winship Cancer Institute | Atlanta30322 | NCT06991556 | Map |
| IL | Associated Urological Specialists | Chicago Ridge60415 | NCT06991556 | Map |
| KS | Wichita Urology Group PA | Wichita67226 | NCT07206056 | Map |
| MD | American Oncology Partners PA Center for Cancer and Blood Disorders | Bethesda20817 | NCT06991556 | Map |
| MA | Mass General Hospital | Boston02114 | NCT06991556 | Map |
| MA | Mass General Hospital | Boston02114 | NCT07206056 | Map |
| MI | Michigan Institute of Urology | West Bloomfield48322 | NCT06991556 | Map |
| NE | XCancer Omaha LLC | Omaha68130 | NCT06991556 | Map |
| NY | Perlmutter Cancer Centre | New York10016 | NCT06991556 | Map |
| NY | Associated Med Professionals of NY | Syracuse13210 | NCT06991556 | Map |
| NY | Montefiore Medical Center | The Bronx10467 | NCT06991556 | Map |
| PA | MidLantic Urology | Bala-Cynwyd19004 | NCT06991556 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT06991556 | Map |
| SC | Carolina Urologic Research Center | Myrtle Beach29572 | NCT06991556 | Map |
| TN | Tennessee Oncology | Nashville37203 | NCT06991556 | Map |
| TX | Urology San Antonio | San Antonio78229 | NCT06991556 | Map |
| VA | Virginia Oncology Associates | Norfolk23502 | NCT06991556 | Map |
| WA | Fred Hutch Cancer Research | Seattle98109 | NCT06991556 | Map |
| WA | Fred Hutchinson Cancer Research Center | Seattle98109-1024 | NCT07206056 | Map |
JSB462 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P1/P2 | 1 | 1 | |
| P2 | 1 | 1 | 2 |
Recruiting JSB462 clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06991556 | An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | P2 | Metastatic Hormone-sensitive Prostate Cancer | 150 | Jul 2025 |
| NCT07206056 | TulmiSTAR-01An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) | P1/P2 | Progressive Metastatic Castrate Resistant Prostate Cancer | 188 | Oct 2025 |
| NCT07174063 | A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer | P1 | Metastatic Prostate Cancer (mCRPC) | 15 | Nov 2025 |
JSB462 clinical trials by indication
Metastatic Prostate Cancer (mCRPC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07174063 | — | P1 | recruiting | A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer |
Progressive Metastatic Castrate Resistant Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07206056 | TulmiSTAR-01 | P1/P2 | recruiting | An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) |
Metastatic Hormone-sensitive Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06991556 | — | P2 | recruiting | An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) |
Prostatic Cancer, Castration-Resistant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07047118 | — | P2 | active not recruiting | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) |
All JSB462 trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06991556 | An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | P2 | recruiting | 150 | Novartis Pharmaceuticals | Jul 2025 | |
| NCT07206056 | TulmiSTAR-01 | An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) | P1/P2 | recruiting | 188 | Novartis Pharmaceuticals | Oct 2025 |
| NCT07047118 | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | P2 | active not recruiting | 138 | Novartis Pharmaceuticals | Jul 2025 | |
| NCT07174063 | A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer | P1 | recruiting | 15 | Novartis Pharmaceuticals | Nov 2025 |
JSB462 clinical trials: frequently asked questions
- How many JSB462 clinical trials are there?
- 4 JSB462 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants.
- Are JSB462 clinical trials recruiting in 2026?
- Yes — 3 JSB462 trials are actively recruiting in 2026, with 27 U.S. sites across 18 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is JSB462 being studied for?
- JSB462 is being studied for Metastatic Hormone-sensitive Prostate Cancer, Metastatic Prostate Cancer (mCRPC), Progressive Metastatic Castrate Resistant Prostate Cancer, Prostatic Cancer, Castration-Resistant. The trials are grouped by indication on this page.
- What phase is JSB462 in?
- JSB462 clinical trials span 2 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors JSB462 clinical trials?
- The lead sponsor across the most JSB462 trials is Novartis Pharmaceuticals. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming JSB462as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: